Efficacy of SynEx Wound Rinse in Civilian Surrogates of Combat Injury Wounds

Official title

Efficacy of SynEx™ Wound Rinse in Civilian Surrogates of Combat Injury Wounds

Overview

The purpose of this interventional study is to compare SynEx Wound Cleanser with the current routine care (Saline) in traumatic wounds. Participants with gunshot, penetrating or burn wounds who participate will be asked to attend up to four study visits, use the assigned wound cleanser and complete brief surveys about their healing and well-being related to the wound healing.

Interventions

• Device SynEx Wound Cleanser
  SynEx is a concentrated form of SynePure®, an FDA 510(k) cleared aqueous, osmotically balanced wound cleanser containing patented chitosan derivatives. The ingredients are USP purified water, chitosan arginine (a patented chitosan derivative), sorbitol powder, and betaine. SynEx cleanser is packaged in a collapsible plastic pouch for reconstitution in water before debriding and cleansing a wound.
• Other Saline
  The saline solution is composed of water and salt. It is packaged in a collapsible plastic pouch.

Primary outcome measures

• Wound healing environment composite score [Time frame: 14 days]

Eligibility criteria

Inclusion criteria

• Acute penetrating, puncture and burn wounds of the upper or lower extremity that meet the inclusion and exclusion criteria for the wound type:

• Penetrating, puncture or laceration wounds: stage II-III (partial to full thickness loss of dermis) excluding diabetic or venous wounds, and pressure ulcers and perforated wounds (except gunshot wounds) and wounds with exposed bones, facia or muscle.
• Gunshot wounds (GSW): Grade I - II on the Red Cross Classification of War Wounds6 (diameter of entry + exit wounds < 10 cm, wound cavity or not, no fracture or fraction without clinically significant comminution). Non-penetrating, penetrating, or perforated GSW are included. GSW with suspected vascular injuries or nerve damage are excluded.
• Burns: partial thickness injury ≤ 9% TBSA. Thermal burn from flame or scald, chemical burns, and electrical burn are included. Radiation and frostbite burns are excluded.
• Males and females ≥18 years old.
• Has access to a computer or mobile device for telepresence visits.
• Able to give informed consent and willing to comply with all required study procedures.

Exclusion criteria

• Any wound likely to require irrigation and debridement in an operating room (OR) setting.
• Concomitant processes sustained contemporaneously with the dermal injury (e.g., inhalational injury requiring ventilation, electrical injury with cardiac damage or arrhythmia, sepsis, traumatic brain injury, other serious or unstabilized organ damage from trauma, etc.).
• > 72 hrs from initial injury.
• Pregnant or lactating females.
• Patients with known allergy(ies) to any of the components of the study irrigation system.
• Patients who are considered by the investigator for any reason to be an unsuitable candidate.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 2 centers

• MedStar Washington Hospital Center — Washington D.C.
• Barnes Jewish Hospital — St Louis

Identifiers

NCT: NCT05743283 · SynEx

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗